Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
2.820
-0.130 (-4.41%)
At close: Mar 3, 2025, 4:00 PM
2.830
+0.010 (0.36%)
After-hours: Mar 3, 2025, 6:05 PM EST
Purple Biotech Employees
Purple Biotech had 19 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$582,900
Market Cap
8.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
PPBT News
- 14 days ago - Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewsWire
- 3 months ago - Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Why Is Purple Biotech Stock Trading Higher On Monday? - Benzinga
- 3 months ago - Purple Biotech Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death - GlobeNewsWire
- 4 months ago - Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 5 months ago - Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire